Abstract
The proto-oncogene Myc serves as a paradigm for understanding the dynamics of transcriptional
regulation. Myc protein has been linked to immune dysfunction, cancer development
and neoplastic transformation. We review recent research regarding functions of Myc
as an important modulator in immune disorders, postallogeneic hematopoietic stem cell
transplantation (HSCT) and several cancers. Myc overexpression has been repeatedly
linked to immune disorders and specific cancers, such as myasthenia gravis, psoriasis,
pemphigus vulgaris, atherosclerosis, long-term allogeneic survival among HSCT patients,
(primary) inflammatory breast cancer, (primary) ovarian carcinoma and hematological
malignancies: acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin’s lymphoma
and diffuse large B-cell lymphoma. However, decreased expression of Myc has been observed
in HSCT patients who did not survive. Understanding impaired or inappropriate expression
of Myc may present a path for the discovery of new targets for therapeutic applications.
Key Indexing Terms
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.Int J Biol Sci. 2014; 10: 1084-1096
- MYC on the path to cancer.Cell. 2012; 149: 22-35
- The N-myconcogene: maximizing its targets, regulation, and therapeutic potential.Mol Cancer Res. 2014; 12: 815-822
- MYC: connecting selective transcriptional control to global RNA production.Nat Rev Cancer. 2015; 15: 593-607
- E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination.Mol Cell. 2002; 9: 1017-1029
- Modulation of c-fos and c-Myc mRNA levels in normal human lymphocytes by calcium ionophore A23187 and phorbol ester.Eur J Immunol. 1986; 16: 1217-1221
- c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.Cell. 2012; 151: 68-79
- Quantitative and qualitative signals determine T-cell cycle entry and progression.Cell Immunol. 1999; 197: 19-29
- Comparative analysis of the intracellular localization of c-Myc, c-Fos, and replicative proteins during cell cycle progression.Mol Cell Biol. 1992; 12: 3548-3555
- Strategically targeting MYC in cancer.F1000Res. 2016; 5 ([pii: F1000 Faculty Rev-408]): 1-7
- The restriction point of the cell cycle.Cell Cycle. 2002; 1: 103-110
- The mysterious human epidermal cell cycle, or an oncogene-induced differentiation checkpoint.Cell Cycle. 2012; 11: 4507-4516
- Genomic targets of the human c-myc protein.Genes Dev. 2003; 17: 1115-1129
- A global transcriptional regulatory role for c-myc in Burkitt’s lymphoma cell.PNAS. 2003; 100: 8164-8169
- Transcriptional amplification in tumor cells with elevated c-Myc.Cell. 2012; 151: 56-67
- Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.Oncogene. 1991; 6: 1915-1922
- Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas.Science. 1992; 257: 212-214
- The role of c-myc in cell growth.CurrOpin Genet Dev. 1993; 3: 44-49
- Cellular MYCro economics: balancing MYC function with MYC expression.Cold Spring Harb Perspect Med. 2013; 3: a014233
- Proteomic profiling of Myc-associated proteins.Cell Cycle. 2010; 9: 4908-4921
- A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs.Cell. 2010; 143: 313-324
- The MYC-WDR5 nexus and cancer.Cancer Res. 2015; 75: 4012-4015
- MYC, metabolism, and cancer.Cancer Discov. 2015; 5: 1024-1039
- Myc and cell cycle control.Biochim BiophysActa. 2015; 1849: 506-516
- Myc’s broad reach.Genes Dev. 2008; 22: 2755-2766
- c-fos, c-myc and IL-2R mRNA expression in PHA activated T lymphocytes treated with a monoclonal anti-HLA class I antibody (MAb 01.65).Biochem Int. 1990; 22: 397-403
- Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?.Cell Cycle. 2009; 8: 1148-1157
- Myc orchestrates a regulatory network required for the establishment and maintenance of pluripotency.Cell Cycle. 2011; 10: 592-597
- Study of the levels of expression of two oncogenes, c-myc and c-myb, in acute and chronic leukemias of both lymphoid and myeloid lineage.Leuk Res. 1985; 9: 833-842
- Decreased steady state c-myc mRNA in activated T cell cultures from old humans is caused by a smaller proportion of T cells that transcribe the c-myc gene.J Immunol. 1990; 144: 3569-3573
- Distinct thresholds govern Myc’s biological output in vivo.Cancer Cell. 2008; 14: 447-457
- Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.Cancer Res. 2008; 8: 5132-5142
- The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression.EMBO J. 2006; 5: 2119-2130
- The c-myc promoter: still Myster Y and challenge.Adv Cancer Res. 2008; 99: 113-333
- The genetic landscape of mutations in Burkitt lymphoma.Nat Genet. 2012; 44: 1321-1325
- Translocations involving c-myc and c-myc function.Oncogene. 2001; 20: 5595-5610
- Inactivation of MYC reverses tumorigenesis.J Intern Med. 2014; 276: 52-60
- Review MYC on the path to cancer.Cell. 2012; 149: 22-35
- Therapeutic strategies to inhibit MYC.Cold Spring Harb Perspect Med. 2014; 4: 1-16
- The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.Immunity. 2011; 35: 871-882
- Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin.EMBO J. 2006; 25: 3298-3309
- Myasthenia gravis—autoantibody characteristics and their implications for therapy.Nat Rev Neurol. 2016; 12: 259-268
- Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology.Blood. 2012; 119: 411-421
- Macrophages and c-Myc cross paths.Oncoimmunology. 2016; 5: e1151991
- Alternative activation of macrophages: an immunologic functional perspective.Annu Rev Immunol. 2009; 27: 451-483
- Exploring the full spectrum of macrophage activation.Nat Rev Immunol. 2008; 8: 958-969
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.Nat Immunol. 2010; 11: 889-896
- New insights into desmosome regulation and pemphigus blistering as a desmosome-remodeling disease.Kaohsiung J Med Sci. 2013; 29: 1-13
- Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease—pemphigus vulgaris.Immunol Invest. 2009; 38: 498-509
- The dual nature of interleukin-10 in pemphigus vulgaris.Cytokine. 2015; 73: 335-341
- Comparison of CD163+ CD206+ M2 macrophages in the lesional skin of bullous pemphigoid and pemphigus vulgaris: the possible pathogenesis of bullous pemphigoid.Dermatology. 2014; 229: 369-378
- Plakoglobin suppresses epithelial proliferation and hair growth in vivo.J Cell Biol. 2000; 149: 503-520
- Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.N Eng J Med. 1982; 306: 1189-1196
- Upregulation of c-myc may contribute to the pathogenesis of canine pemphigus vulgaris.Vet Derm. 2007; 118: 12-17
- An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris.Exp Dermatol. 2009; 18: 771-780
- MYC in mammalian epidermis: how can an oncogene stimulate differentiation?.Nat Rev Cancer. 2008; 8: 234-242
- Desmogleins 1 and 3 in the companion layer anchor mouse anagen hair to the follicle.J Invest Dermatol. 2004; 123: 817-822
- An adult passive transfer mouse model to study desmoglein 3 signaling in pemphigus vulgaris.See comment in PubMed Commons belowJ Invest Dermatol. 2012; 132: 346-355
- Preclinical studies identify non-apoptotic low-level caspase-3 as therapeutic target in pemphigus vulgaris.PLoS One. 2015; 10: e0119809
- The modulation of skin irritation.Contact Derm. 1994; 31: 281-287
- Overview of psoriasis.Dermatol Ther. 2004; 17: 341-349
- Nuclear c-Myc a molecular marker of early stage pemphigus vulgaris.J of Invest Derma. 2007; 127: 1549-1555
- Review on toll-like receptor activation in myasthenia gravis: application to the development of new experimental models.Clin Rev Allergy Immunol. 2017; 52: 133-147
- Etiology of myasthenia gravis: innate immunity signature in pathological thymus.Autoimmun Rev. 2013; 12: 863-874
- Innate immunity in myasthenia gravis thymus: pathogenic effects of toll-like receptor 4 signaling on autoimmunity.J Autoimmun. 2014; 52: 74-89
- Decreased expression of c-myc family genes in thymuses from myasthenia gravis patients.J Neuroimmunol. 2001; 115: 199-202
- Expression of c-myc, c-Ki-ras and c-Ha-ras oncogene products in peripheral blood mononuclear cells from patients with myasthenia gravis.Intern Med. 1993; 32: 519-522
- Transcriptional repression of IFN regulatory factor 7 by MYC is critical for type I IFN production in human plasmacytoid dendritic cells.J Immunol. 2016; 197: 3348-3359
- Interferon system and natural killer cell activity in myasthenia gravis.Q J Med. 1990; 76: 951-960
- Retrovirus-like particles in human thymomas.Tokai J ExpClin Med. 1990; 15: 219-225
- Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-ll (NK-15) antigens.J Immunol. 1983; 131: 1789
- Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.BMC Med Genomics. 2015; 8: 13
- Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis.J Cell Mol Med. 2014; 18: 991-1003
- Early cell-cycle gene expression in T-cells after hematopoietic stem cell transplantation.Transpl Immuno. 2013; 24: 146-154
- Myc and AP-1 expressionin T-cells and T-cell activation in patients after hematopoietic stem cell transplantation.Clin Exp Med. 2015; 15: 189-203
- Macrophages in vascular inflammation: from atherosclerosis to vasculitis.Autoimmunity. 2015; 48: 139-151
- Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.Angiology. 2007; 58: 513-522
- Induction of cell cycle-dependent genes during cell cycle progression of arterial smooth muscle cells in culture.J Cell Physiol. 1991; 146: 356-361
- Dissociation between activation of growth related genes and mitogenic responses of neonatal vascular smooth muscle cells.Biochem Biophys Res Commun. 1991; 181: 617-622
- Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders.Cell Cycle. 2006; 5: 1621-1628
- The pathogenesis of atherosclerosis: an update.N Engl J Med. 1986; 314: 488-500
- The pathogenesis of coronary artery disease and the acute coronary syndrome.N Engl J Med. 1992; 326: 242-318
- Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display expression of the MYC proto-oncogene.J Pathol. 1991; 138: 765-775
- Distribution of c-myc oncoprotein in healthy and atherosclerotic human carotid arteries.J Vasc Surg. 1993; 18: 170-177
- Regulation of oncogene expression in cultured aortic smooth muscle cells.J Biol Chem. 1986; 261: 12865-12868
- Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal.Am J Pathol. 1990; 137: 761-765
- Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles.Nature. 2014; 24: 483-487
- Cell cycle alterations and lung cancer.Histol Histopathol. 2006; 21: 423-435
- Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.Clin Canc Res. 2004; 10: 6789-6795
- Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors.Proc Natl Acad Sci U S A. 2003; 100: 7331-7336
- Oncogenic pathways in hereditary and sporadic breast cancer.Maturitas. 2008; 61: 141-150
- Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape.Cancer Biomark. 2009; 5: 41-49
- Oncogene protein co-expression: value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.Ann Surg. 1995; 221: 706-720
- Inflammatory breast cancer (IBC): clues for targeted therapies.Breast Cancer Res Treat. 2013; 140: 23-33
- WDR5 Supports an N-Myc transcriptional complex that drives a protumorigenic gene expression signature in neuroblastoma.Cancer Res. 2015; 75: 5143-5154
- c-MYC is a radiosensitive locus in human breast cells.Oncogene. 2015; 34: 4985-4994
- Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.Radiat Oncol. 2011; 6: 168
- Radiation-associated breast tumors display a distinct gene expression profile.Int J Radiat Oncol Biol Phys. 2010; 76: 540-547
- Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.PLoS One. 2010; 5: e9201
- Myc amplification in ovarian cancer.Gynecol Oncol. 1990; 38: 340-342
- Targeting c-MYC in platinum-resistant ovarian cancer.Mol Cancer Ther. 2015; 14: 2260-2269
- The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.PLoS One. 2014; 9: e89841
- Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival.Hematol Oncol. 2016; ([Epub ahead of print])https://doi.org/10.1002/hon.2279
- Acute myeloid leukemia: a concise review.J Clin Med. 2016; : 5
- ADCY7 supports development of acute myeloid leukemia.Biochem Biophys Res Commun. 2015; 465: 47-52
- An overview and update of chronic myeloid leukemia for primary care physicians.KoreanJ Fam Med. 2015; 36: 197-202
- BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.Mol Cancer. 2015; 14: 132
- Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.EMBO J. 2007; 26: 1456-1466
- Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.N Engl J Med. 2004; 351: 657-667
- Hodgkin lymphoma: diagnosis and treatment.Mayo Clin Proc. 2015; 90: 1574-1583
- Diffuse large B-cell lymphoma version 1.2016.J Natl Compr Canc Netw. 2016; 14: 196-231
- Expression profiles of MYC protein and MYC gene rearrangement in lymphomas.Am J Surg Pathol. 2015; 39: 294-303
Article info
Publication history
Published online: July 06, 2017
Accepted:
June 14,
2017
Received:
February 23,
2017
Footnotes
☆The authors declared no competing financial interests.
Identification
Copyright
© 2017 Southern Society for Clinical Investigation. Published by All rights reserved.
